Related Experiment Video
Updated: May 21, 2026

19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
18.4K
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study
Si Ahmed Si Nafa1, Souad Benali1, Guillaume Penaranda2
1Department of Hepato-Gastroenterology, Hospital Saint Joseph, Marseille, France.
Journal of Viral Hepatitis
|May 21, 2025
Summary
Universal screening for hepatitis C virus (HCV) in French hospitals is more effective and cost-effective than routine screening, despite higher initial costs. This approach identifies more infections and cures, proving beneficial for public health.
Area of Science:
- Hepatology and Infectious Diseases
- Public Health and Epidemiology
- Health Economics
Background:
- Hepatitis C virus (HCV) infection treatment in France is accessible, but screening relies on risk factors, making universal screening debated.
- Hospitalized patients represent a population with potentially higher HCV prevalence than the general population.
- Assessing the cost-effectiveness of universal screening in a hospital setting is crucial for optimizing public health strategies.
Purpose of the Study:
- To evaluate the effectiveness and cost-benefit of universal HCV screening among hospitalized patients in France.
- To determine the prevalence of HCV infection within this specific patient cohort.
- To compare universal screening with traditional, risk-based screening methods.
Main Methods:
- Prospective DEVICHO study conducted from November 2019 to November 2021 across 22 hospital departments.
- Universal screening for HCV offered to all hospitalized patients, with data compared to patients screened outside the study.
- Analysis included HCV antibody (HCV-Ab) and RNA positivity, treatment rates, sustained virological response, and cost-effectiveness calculations.
Main Results:
- A total of 25,663 patients were invited, with 19.4% (Group 1) participating in universal screening vs. 7% (Group 2) in routine screening.
- HCV-Ab positivity was 2.9% (199/6789), with 14.6% (29/199) of those being HCV-RNA positive (viremic).
- Universal screening was more effective and cost-effective (€11,060 per RNA infection, €36,600 per cure) than routine screening, despite higher upfront costs.
Conclusions:
- Hospital-based universal HCV screening is efficient, identifying a higher prevalence of infection compared to the general population.
- The strategy is cost-effective, with costs per identified infection and cure below France's GDP per capita.
- Healthcare professional engagement and improved linkage to care are critical barriers to overcome for successful implementation.
More Related Videos
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

